The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Abstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many indications, the toxicities of the current t...

Full description

Bibliographic Details
Main Authors: Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan, Christina Furebring, Per Norlén, Peter Ellmark
Format: Article
Language:English
Published: BMJ Publishing Group 2019-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
CTLA-4
OX40
Regulatory T cell
Solid tumors
Online Access:http://link.springer.com/article/10.1186/s40425-019-0570-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0570-8

Similar Items